VIEWPOINTS

Volker Wacheck Discusses the Approval of the Lonsurf Combination Drug for the Treatment of Colorectal Cancer

Shots: Volker Wacheck sheds light on the recent approval of Lonsurf in combination with bevacizumab for patients with metastatic colorectal cancer While sharing key insights from the pivotal P-III (SUNLIGHT) trial evaluating Lonsurf ± bevacizumab, Volker reveals that the combination drug is proven to prolong both OS and PFS along with QoL benefits and a…

January 2, 2024

Women Health: Amy Taneja in a Striking Conversation with PharmaShots Shares the Highlights of Jada System

Shots: Amy Taneja, in a stimulating conversation with PharmaShots, shares the highlights of the Jada system, a vacuum-induced hemorrhage control device Amy describes how the Jada system differs from traditional methods of controlling PPH while explaining how the system works JADA, which is now being shipped to Chile, Hong Kong, Puerto Rico, New Zealand, and…

December 26, 2023

Justin Schreiber Discusses the Recently Launched D2C Telehealth Model for Hormone Therapy

Shots: Justin Schreiber, Chairman, and CEO of, LifeMD, in an illuminating conversation with PharmaShots, discusses the recent partnership with ASCEND Therapeutics LifeMD, a virtual primary care company, and ASCEND Therapeutics, a leading women's health pharmaceutical company, came together to bring an integrated direct-to-consumer telehealth model to enhance the way women receive care for their menopause…

December 21, 2023

Dr. Lotus Mallbris Discusses Positive Results from the VIVID-1 P-III Study of Mirikizumab for the Treatment of Crohn’s Disease in Adults

Shots: Dr. Lotus Mallbris shares the positive endpoint results of the VIVID-1 P-III study, evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn’s disease While shedding light on the mechanism of mirkizumab, Lotus highlights that available therapies to treat Crohn’s disease often fail to achieve clinical…

December 19, 2023

Paul Moss Shares Insights from RWE Inform Study from AstraZeneca at IDWeek 2023

Shots: Paul Moss Professor of Hematology and Deputy Head of the College of Medicine at the University of Birmingham, shares insights from the RWE INFORM study from AstraZeneca INFORM used record data from 12 million people in the UK to study the relative risk of severe COVID-19 infection in patients with immune suppression Even though…

December 18, 2023

Helen Yeh & Naim Shehadeh in a Stirring Conversation with PharmaShots, Highlight the Results from T2NOW Study

Shots: At the EASD, AZ announced positive results from the T2NOW P-III study that evaluated the efficacy and safety of Forxiga as an add-on treatment in children and adolescents with T2D receiving metformin, insulin, or both Helen Yeh, VP, CVRM Therapy Area Biopharmaceuticals Medical at AstraZeneca, and Naim Shehadeh, Professor of Endocrinology, Rambam Health Care…

December 11, 2023

Kylen Cieslak and Robert Ley Discuss the Expansion of Thermo Fisher Scientific’s Services Central in the US & EU

Shots: Kylen Cieslak, Senior Manager, Service Marketing, Thermo Fisher Scientific, and Robert Ley, Senior Strategic Product Manager, Thermo Fisher Scientific in a stirring conversation with PharmaShots Kylen and Robert highlighted the recent expansion of Thermo Fisher Scientific’s Services Central in the United States and Europe Services Central is an online platform intended to provide 24/7…

December 7, 2023

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots

Shots: Mohamed Eid, VP of Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, at Boehringer Ingelheim, in a stimulating conversation with PharmaShots sheds light on the recent approval of Jardiance for the treatment of adults with chronic kidney disease Jardiance’s EMPA Kidney P-III trial results demonstrated a 28% relative risk reduction vs placebo. Jardiance…

December 5, 2023

Andrew Menzies-Gow Shares Insights from Phase III MANDARA Trial of Fasenra for EGPA Patients

Shots While sharing the details on Fasenra, Andrew highlights the unmet medical need in the healthcare sector as there’s only one approved treatment for EGPA With mepolizumab as the comparator drug for the trial, Andrew shares the positive results in achieving remission rates. Andrew sheds light on the unique mechanism of benralizumab that directly targets…

December 4, 2023

In an Insightful Conversation with PharmaShots, Betty Woo Highlights Thermo Fisher’s Cell Therapy Collaboration Program

Shots: Betty Woo, VP of Cell, Gene, and Advanced Therapies, Thermo Fisher Scientific discusses the evolution of ThermoFisher’s strategic collaboration with ArsenalBio Betty highlights the development of programmable autologous T cells for the treatment of cancer and the cell therapy collaboration program Betty believes that through innovation and partnership, they can tap into the full…

November 30, 2023